Anzeige
Mehr »
Mittwoch, 13.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DFK1 | ISIN: IL0011809592 | Ticker-Symbol: H1Z
Frankfurt
13.08.25 | 08:07
0,910 Euro
-5,21 % -0,050
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NEUROSENSE THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
NEUROSENSE THERAPEUTICS LTD 5-Tage-Chart

Aktuelle News zur NEUROSENSE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.08.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer3
10.07.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer1
NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln
26.06.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer1
12.05.This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday19
12.05.Boral Capital starts NeuroSense stock with Buy, $14 target12
07.05.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer-
24.04.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer2
24.04.NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update140Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about...
► Artikel lesen
09.04.NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment259New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS. CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/...
► Artikel lesen
08.04.NeuroSense Therapeutics GAAP EPS of -$0.543
07.04.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer1
07.04.NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates136Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership...
► Artikel lesen
07.04.NeuroSense Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers-
27.03.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer3
25.03.XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 25.03.2025502The following instruments on XETRA do have their first trading 25.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.03.2025 Aktien 1 US50125G1094 KULR Technology Group...
► Artikel lesen
19.03.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer1
19.02.NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer3
18.12.24NeuroSense Provides Business Update and Third Quarter 2024 Financial Results189CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing...
► Artikel lesen
11.12.24NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC179The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 ...
► Artikel lesen
28.10.24NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission166Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial success Parallel...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1